The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology (ASGO), the Korean Society of Gynecologic Onco...
In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Baldwin and colleagues titled Evaluation of the Role of Liver Metastasectomy in the Treatment of Stage IV Endometrial Cancer. Using data from the National Cancer Database, the researchers analyzed outcomes in 999 patients with metastatic endometrial cancer confined to the liver. The study found that patients who underwent both chemotherapy and surgical removal of liver metastases had improved survival compared to those who received chemotherapy alone, with a median survival of 20.1 months versus 14.6 months. While the findings suggest a potential benefit of metastasectomy, adjusted analysis did not reach statistical significance, highlighting the need for further prospective studies. Tune in to learn more about the evolving role of surgery in metastatic endometrial cancer treatment.Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer
--------
4:39
JGO Weekly Summary (March 11, 2025)
This episode explores a recent study on the increased risk of cardiovascular disease among adolescent and young adult survivors of cervical cancer. Using data from the Korean National Health Insurance Service, researchers found that these survivors face a 47% higher risk of cardiovascular disease compared to non-cancer controls, with those receiving chemoradiotherapy at particularly high risk for heart failure, ischemic heart disease, and venous thromboembolism. The findings highlight the need for long-term cardiovascular monitoring and preventive care in this population. Tune in to learn more about the implications for survivorship care.Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer
--------
5:09
JGO Weekly Summary (March 4, 2025)
This episode discusses a multi-institutional study evaluating the impact of bevacizumab in frontline chemotherapy for advanced ovarian clear cell carcinoma. Researchers analyzed data from 178 patients treated between 2008 and 2018 and found that adding bevacizumab significantly improved progression-free and overall survival. Patients who received bevacizumab had a median progression-free survival of 29.7 months compared to 10.5 months in those who did not. Median overall survival was 51.4 months versus 27.4 months. These findings suggest that bevacizumab may be an effective addition to first-line treatment for this rare and chemoresistant ovarian cancer. Tune in to learn more about the study and its clinical implications.Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: A multicenter retrospective analysis
--------
5:35
JGO Weekly Summary (February 25, 2025)
In this episode of the Journal of Gynecologic Oncology podcast, we discuss a study by Kanno and colleagues examining the impact of cytoreductive surgery on outcomes in high tumor burden ovarian cancer following the introduction of poly ADP-ribose polymerase inhibitors. This retrospective analysis of 434 patients found that, while complete cytoreduction remains essential, the use of poly ADP-ribose polymerase inhibitors may improve progression-free survival for patients with extensive tumor burden. However, higher surgical complexity was associated with increased complication rates. These findings highlight the evolving role of maintenance therapy and the importance of optimizing surgical approaches to enhance patient outcomes. Tune in to learn more about the implications for clinical practice in the poly ADP-ribose polymerase inhibitor era.The Impact of Cytoreductive Surgery on outcomes in High Tumor Burden Ovarian Cancer after induction of PARP inhibitors
--------
5:41
JGO Weekly Summary (February 18, 2025)
This episode of the Journal of Gynecologic Oncology podcast explores a study by Berthet and colleagues on the role of platinum-free interval in predicting the benefit of second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma. Analyzing a retrospective cohort of 40 patients, the study found that patients with a progression-free survival of more than nine months had a significantly longer overall survival after relapse when treated with platinum- or anthracycline-based chemotherapy. In contrast, those with earlier recurrence derived little benefit from additional chemotherapy, with outcomes comparable to patients receiving only best supportive care. These findings suggest that platinum-free interval could serve as a useful marker to guide treatment decisions. Tune in for a discussion on the clinical implications, potential therapeutic targets, and the future of individualized treatment strategies in gynecologic carcinosarcoma.Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis.
The Journal of Gynecologic Oncology (JGO) is an official publication of the Asian Society of Gynecologic Oncology (ASGO), the Korean Society of Gynecologic Oncology (KSGO), the Japan Society of Gynecologic Oncology (JSGO), and the Society of Gynecologic Oncology of Canada (GOC).
Brasil